Malignant Female Reproductive System Neoplasm Clinical Trials

11 recruiting

Malignant Female Reproductive System Neoplasm Trials at a Glance

12 actively recruiting trials for malignant female reproductive system neoplasm are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Houston, Columbus, and Baltimore. Lead sponsors running malignant female reproductive system neoplasm studies include Mayo Clinic, M.D. Anderson Cancer Center, and National Cancer Institute (NCI).

Browse malignant female reproductive system neoplasm trials by phase

Treatments under study

About Malignant Female Reproductive System Neoplasm Clinical Trials

Looking for clinical trials for Malignant Female Reproductive System Neoplasm? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Malignant Female Reproductive System Neoplasm trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Malignant Female Reproductive System Neoplasm clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 2

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

Malignant Solid NeoplasmMalignant Female Reproductive System NeoplasmRecurrent Malignant Solid Neoplasm+1 more
National Cancer Institute (NCI)70 enrolled185 locationsNCT06126276
Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 2

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

Anal CarcinomaCervical CarcinomaVaginal Carcinoma+3 more
Ohio State University Comprehensive Cancer Center25 enrolled1 locationNCT07407647
Recruiting

Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study

Malignant Female Reproductive System NeoplasmMalignant Genitourinary System NeoplasmMalignant Digestive System Neoplasm
Wake Forest University Health Sciences500 enrolled59 locationsNCT07215624
Recruiting
Not Applicable

Cancer Genetic Testing in Ethnic Populations

Breast CarcinomaHead and Neck CarcinomaMalignant Brain Neoplasm+8 more
Mayo Clinic1,800 enrolled2 locationsNCT04475640
Recruiting
Phase 1

Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

Malignant Female Reproductive System NeoplasmStage IV Cervical Cancer AJCC v8Stage IVA Cervical Cancer AJCC v8+22 more
M.D. Anderson Cancer Center24 enrolled2 locationsNCT03968406
Recruiting
Phase 4

Methadone Versus Intrathecal Hydromorphone for Postoperative Pain Relief in Gynecologic Cancer Undergoing Surgery

Malignant Female Reproductive System Neoplasm
Mayo Clinic140 enrolled1 locationNCT06525740
Recruiting
Phase 2

Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal or Gynecological Cancer

Malignant Female Reproductive System NeoplasmMalignant Digestive System Neoplasm
Mayo Clinic34 enrolled1 locationNCT06855524
Recruiting

PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery

Malignant Female Reproductive System NeoplasmGynecologic CancerGynecologic Neoplasm
University of California, San Francisco500 enrolled2 locationsNCT06089083
Recruiting
Phase 1

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+71 more
M.D. Anderson Cancer Center43 enrolled1 locationNCT05092373
Recruiting
Phase 3

REmotely-delivered Supportive Programs for Improving Surgical Pain and disTrEss

Malignant Female Reproductive System NeoplasmAnxietySleep Disturbance+2 more
Wake Forest University Health Sciences160 enrolled2 locationsNCT05625360
Recruiting
Not Applicable

An Individualized Online Home-Based Exercise Program for Improving Symptoms in Gynecologic Cancer Survivors

Malignant Female Reproductive System Neoplasm
Emory University40 enrolled4 locationsNCT06709534